Opinion|Videos|October 28, 2024
Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels
Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of luspatercept in the RS-negative population? When do you consider it as first-line treatment in this particular patient population?
Resource link: COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).
Resource link: Platzbecker U, et al. Phase II PACE-MDS study. J Clin Oncol, 2022.
Resource link: Platzbecker U, et al. Comparative biomarkers by RS status COMMANDS trial. EHA 2024, abstract P763.
- How do EPO levels factor into your treatment approach for this patient
- Please comment on outcomes in the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024) based on EPO levels (<200).
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5